LINC01565
Protein GR6
Also known as: GR6_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for LINC01565 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
149 residues, UniProt reviewed canonical sequence.
>O15544|LINC01565
1 MKEALHQIVV RCSELVSSTS LPRLSVSRLQ GPPDSQPLGT LGQGGWKLLG IVGSLAPETL
61 GGLGTEFGPC THPLPFDMVR ERERDDELRQ GWLLQCPQCA RTLLCHCGPF LTPPSQTSSS
121 GFQLCSLKPS GSLVTATEPL SNFAFSYFPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LINC01565 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.69
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LINC01565 as an antibody target. Whether an autoantibody or antibody against LINC01565 could matter depends on whether native LINC01565 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LINC01565 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LINC01565 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...